ASP Isotopes Inc美股招股说明书(2025-06-02版)

Our common stock is listed on The Nasdaq Capital Market, or “Nasdaq,” under the symbol “ASPI.” On May 30, 2025, the lassale price of shares of our common stock on Nasdaq was $7.56 per share. supplement and in our filings with the Securities and Exchange Commission that are incorporated by reference in this psupplement and the accompanying prospectus to read about factors you should consider before buying shares of our common s Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved to the contrary is a criminal offense.Per Share Underwriting Discounts and Commissions(1)$0.399Proceeds to ASP Isotopes Inc. (before expenses)$6.251________________________________________(1)We refer you to “Underwriting” beginning on page S-17 of this prospectus supplement for additional information regarding unde The underwriters expect to deliver the shares to purchasers on or about June3, 2025. writing prospectus that we have authorized for use in connection with this offering, and the information incorporated by reference asunder the headings “Where You Can Find More Information” and “Incorporation of Certain Information by Reference” in this psupplement. These documents contain important information that you should consider when making your investment decision.This prospectus supplement and the accompanying prospectus are part of a “shelf” registration statement on Form S-3 (File286860) that was declared effective by the Securities and Exchange Commission, or the “SEC,” on May30, 2025. This document is cof two parts. The first part is this prospectus supplement, which describes the specific terms of this offering and also adds to, an information incorporated by reference is considered to be a part of this prospectus supplement and the accompanying prospectus andread with the same care. When we make future filings with the SEC to update the information contained in documents that hincorporated by reference, the information included or incorporated by reference in this prospectus supplement is considered to be autoupdated and superseded. In other words, in case of a conflict or inconsistency between information contained in this prospectus suppleinformation in the accompanying prospectus or incorporated by reference into this prospectus supplement, you should rely on the incontained in the document that was filed later.We have not, and the underwriters have not, authorized anyone to provide any information other than that contained or incorp supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering ofstock and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. condition, results of operations and prospects may have changed since those dates.Unless the context otherwise indicates, references in this prospectus to “we,” “our” and “us” refer to ASP Isotopes Inc., a accompanying prospectus and any free writing prospectus, as well as the information incorporated by reference, before deciding winvest in shares of our common stock. You should pay special attention to the “Risk Factors” section beginning on page S-7 of this psupplement and in our Annual Report on Form 10-K for the year ended December 31, 2024, as revised or supplemented by our su financial statements and notes to those consolidated financial statements and the other information incorporated by referenceprospectus supplement and the accompanying prospectus, before making an investment decision.OverviewWe are a development stage advanced materials company dedicated to the development of technology and processesuccessful, will allow for the enrichment of natural isotopes into higher concentration products, which could be used in several indusproprietary technologies, the Aerodynamic Separation Process (“ASP technology”) and Quantum Enrichment technology (“QE tech enriched Yb-176 at our Yb-176 enrichment facility in Pretoria, South Africa. Our C-14 and Si-28 enrichment facilities utilizetechnology and our Yb-176 enrichment facility utilizes QE technology. We expect our first three enrichment facilities to generate coproduct during 2025. In addition, we have started planning additional isotope enrichment plants both in South Africa and in other juriincluding Iceland and the United States. We believe the C-14 we may produce using the ASP technology could be used in the develo In addition, we are considering the future development of the ASP technology for the separation of Zinc-68 and Xenon-12potential use in the healthcare end market, Germanium 70/72/74 for potential use in the semiconductor end market, and Chlorinpotential use in the nuclear energy end market. We are also considering the future development of QE technology for the separation o64, Gadolinium-160, Ytterbium-171, Lithium 6 and Lithium7.We are currently pursuing an initiative to apply our enrichment technologies to the